438 related articles for article (PubMed ID: 20416367)
1. Co-delivery of doxorubicin and plasmid by a novel FGFR-mediated cationic liposome.
Xiao W; Chen X; Yang L; Mao Y; Wei Y; Chen L
Int J Pharm; 2010 Jun; 393(1-2):119-26. PubMed ID: 20416367
[TBL] [Abstract][Full Text] [Related]
2. Improved tumor-targeting drug delivery and therapeutic efficacy by cationic liposome modified with truncated bFGF peptide.
Chen X; Wang X; Wang Y; Yang L; Hu J; Xiao W; Fu A; Cai L; Li X; Ye X; Liu Y; Wu W; Shao X; Mao Y; Wei Y; Chen L
J Control Release; 2010 Jul; 145(1):17-25. PubMed ID: 20307599
[TBL] [Abstract][Full Text] [Related]
3. Plasmid pORF-hTRAIL and doxorubicin co-delivery targeting to tumor using peptide-conjugated polyamidoamine dendrimer.
Han L; Huang R; Li J; Liu S; Huang S; Jiang C
Biomaterials; 2011 Feb; 32(4):1242-52. PubMed ID: 20971503
[TBL] [Abstract][Full Text] [Related]
4. Vascular targeting of doxorubicin using cationic liposomes.
Wu J; Lee A; Lu Y; Lee RJ
Int J Pharm; 2007 Jun; 337(1-2):329-35. PubMed ID: 17275230
[TBL] [Abstract][Full Text] [Related]
5. Polyethylene glycol-complexed cationic liposome for enhanced cellular uptake and anticancer activity.
Jung SH; Jung SH; Seong H; Cho SH; Jeong KS; Shin BC
Int J Pharm; 2009 Dec; 382(1-2):254-61. PubMed ID: 19666094
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of liposomes and hyperthermia in a human tumor xenograft model: importance of triggered drug release.
Kong G; Anyarambhatla G; Petros WP; Braun RD; Colvin OM; Needham D; Dewhirst MW
Cancer Res; 2000 Dec; 60(24):6950-7. PubMed ID: 11156395
[TBL] [Abstract][Full Text] [Related]
7. Anti-angiogenic therapy via cationic liposome-mediated systemic siRNA delivery.
Tagami T; Suzuki T; Matsunaga M; Nakamura K; Moriyoshi N; Ishida T; Kiwada H
Int J Pharm; 2012 Jan; 422(1-2):280-9. PubMed ID: 22101286
[TBL] [Abstract][Full Text] [Related]
8. The use of cationic MPEG-PCL-g-PEI micelles for co-delivery of Msurvivin T34A gene and doxorubicin.
Shi S; Shi K; Tan L; Qu Y; Shen G; Chu B; Zhang S; Su X; Li X; Wei Y; Qian Z
Biomaterials; 2014 May; 35(15):4536-47. PubMed ID: 24582554
[TBL] [Abstract][Full Text] [Related]
9. [Targeting therapy of magnetic doxorubicin liposome in nude mice bearing colon cancer].
Zhou PH; Yao LQ; Qin XY; Shen XZ; Liu YS; Lu WY; Yao M
Zhonghua Yi Xue Za Zhi; 2003 Dec; 83(23):2073-6. PubMed ID: 14703420
[TBL] [Abstract][Full Text] [Related]
10. Involvement of doxorubicin-induced Fas expression in the antitumor effect of doxorubicin on Lewis lung carcinoma in vivo.
Yoshimoto Y; Kawada M; Ikeda D; Ishizuka M
Int Immunopharmacol; 2005 Feb; 5(2):281-8. PubMed ID: 15652759
[TBL] [Abstract][Full Text] [Related]
11. In vivo anti-tumor effect of PEG liposomal doxorubicin (DOX) in DOX-resistant tumor-bearing mice: Involvement of cytotoxic effect on vascular endothelial cells.
Ogawara K; Un K; Tanaka K; Higaki K; Kimura T
J Control Release; 2009 Jan; 133(1):4-10. PubMed ID: 18840484
[TBL] [Abstract][Full Text] [Related]
12. Efficient inhibition of murine breast cancer growth and metastasis by gene transferred mouse survivin Thr34-->Ala mutant.
Peng XC; Yang L; Yang LP; Mao YQ; Yang HS; Liu JY; Zhang DM; Chen LJ; Wei YQ
J Exp Clin Cancer Res; 2008 Sep; 27(1):46. PubMed ID: 18816410
[TBL] [Abstract][Full Text] [Related]
13. Development of cationic liposome formulations for intratracheal gene therapy of early lung cancer.
Zou Y; Zong G; Ling YH; Perez-Soler R
Cancer Gene Ther; 2000 May; 7(5):683-96. PubMed ID: 10830716
[TBL] [Abstract][Full Text] [Related]
14. Folate-mediated poly(3-hydroxybutyrate-co-3-hydroxyoctanoate) nanoparticles for targeting drug delivery.
Zhang C; Zhao L; Dong Y; Zhang X; Lin J; Chen Z
Eur J Pharm Biopharm; 2010 Sep; 76(1):10-6. PubMed ID: 20472060
[TBL] [Abstract][Full Text] [Related]
15. A cationic prodrug/therapeutic gene nanocomplex for the synergistic treatment of tumors.
Lu X; Wang QQ; Xu FJ; Tang GP; Yang WT
Biomaterials; 2011 Jul; 32(21):4849-56. PubMed ID: 21458064
[TBL] [Abstract][Full Text] [Related]
16. In vivo evaluation of a new polymer-lipid hybrid nanoparticle (PLN) formulation of doxorubicin in a murine solid tumor model.
Wong HL; Rauth AM; Bendayan R; Wu XY
Eur J Pharm Biopharm; 2007 Mar; 65(3):300-8. PubMed ID: 17156986
[TBL] [Abstract][Full Text] [Related]
17. PNAS-4, a novel pro-apoptotic gene, can potentiate antineoplastic effects of cisplatin.
Yuan Z; Yan F; Wang YS; Liu HY; Gou LT; Zhao XY; Lai ST; Deng HX; Li J; Ding ZY; Xiong SQ; Kan B; Mao YQ; Chen LJ; Wei YQ; Zhao X
Cancer Chemother Pharmacol; 2009 Dec; 65(1):13-25. PubMed ID: 19387645
[TBL] [Abstract][Full Text] [Related]
18. Cationic polymeric gene delivery of beta-glucuronidase for doxorubicin prodrug therapy.
Fonseca MJ; Storm G; Hennink WE; Gerritsen WR; Haisma HJ
J Gene Med; 1999; 1(6):407-14. PubMed ID: 10753066
[TBL] [Abstract][Full Text] [Related]
19. Simultaneous delivery of doxorubicin and immunostimulatory CpG motif to tumors using a plasmid DNA/doxorubicin complex in mice.
Mizuno Y; Naoi T; Nishikawa M; Rattanakiat S; Hamaguchi N; Hashida M; Takakura Y
J Control Release; 2010 Jan; 141(2):252-9. PubMed ID: 19778560
[TBL] [Abstract][Full Text] [Related]
20. Anti-tumor effect of pEgr-interferon-gamma-endostatin gene-radiotherapy in mice bearing Lewis lung carcinoma and its mechanism.
Yang W; Li XY
Chin Med J (Engl); 2005 Feb; 118(4):296-301. PubMed ID: 15740667
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
